Skip to main content
Top
Published in: Annals of Surgical Oncology 8/2016

01-08-2016 | Urologic Oncology

Prostate Health Index and %p2PSA Predict Aggressive Prostate Cancer Pathology in Chinese Patients Undergoing Radical Prostatectomy

Authors: Peter Ka-Fung Chiu, MBChB, FRCSEd (Urol), FHKAM (Surg), Fernand Mac-Moune Lai, MD (Lyon), FRCPA, FHKCPath, MScFl (Leicester), Jeremy Yuen-Chun Teoh, MBBS, MRCSEd, Wai-Man Lee, Msc, Chi-Hang Yee, MBBS, FRCSEd (Urol), FHKAM (Surg), Eddie Shu-Yin Chan, MD, MBChB, FRCSEd (Urol), FHKAM (Surg), See-Ming Hou, MBBS, FRCSEd (Urol), FHKAM (Surg), Chi-Fai Ng, MD, MBChB, FRCSEd (Urol), FHKAM (Surg)

Published in: Annals of Surgical Oncology | Issue 8/2016

Login to get access

Abstract

Purpose

To investigate the performance of prostate health index (PHI) and percentage prostate-specific antigen (PSA) isoform [−2]proPSA (%p2PSA) in predicting pathologic outcomes at radical prostatectomy (RP) in a Chinese population.

Methods

We performed a prospective study of 135 prostate cancer patients with RP. The accuracy of preoperative %p2PSA (= p2PSA/free PSA) and PHI [= (p2PSA/free PSA) × √PSA] in predicting pathologic outcomes of RP including pT3 disease, pathologic Gleason score (pGS) ≥7, Gleason score (GS) upgrade at RP, tumor volume >0.5 ml, and Epstein criteria for significant tumor were calculated using multivariate analyses and area under the curve. The base model in multivariate analysis included age, PSA, abnormal digital rectal examination, and biopsy GS.

Results

PHI was significantly higher in patients with pT3 or pGS ≥ 7 (p < 0.001), pT3 disease (p = 0.001), pGS ≥ 7 (p < 0.001), GS upgrade (p < 0.001), tumor volume >0.5 ml (p < 0.001), and Epstein criteria for significant tumor (p = 0.001). %p2PSA was also significantly higher in all the above outcomes. The risk of pT3 or pGS ≥ 7 was 16.1 % for PHI < 35 and 60.8 % for PHI > 35 (sensitivity 84.2 %, specificity of 60.3 %), and the risk of tumor volume >0.5 ml was 25.5 % for PHI < 35 and 72.6 % for PHI > 35 (sensitivity 79.1 %, specificity 67.2 %). In multivariate analysis, adding %p2PSA or PHI to the base model significantly improved the accuracy (area under the curve) in predicting pT3 or pGS ≥ 7 (by 7.2–7.9 %), tumor volume >0.5 ml (by 10.3–12.8 %), and Epstein criteria for significant tumor (by 13.9–15.9 %). Net clinical benefit was observed in decision curve analyses for prediction of both tumor volume >0.5 ml, and pT3 or pGS ≥ 7.

Conclusions

Both PHI and %p2PSA predict aggressive and significant pathologies in RP in Chinese men. This enabled identification of nonaggressive cancers for better counseling on active surveillance or treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jansen FH, vanSchaik RHN, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol. 2010;57:921–7.CrossRefPubMed Jansen FH, vanSchaik RHN, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol. 2010;57:921–7.CrossRefPubMed
2.
go back to reference Le BV, Griffin CR, Loeb S, et al. [−2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol. 2010;183:1355–9.CrossRefPubMedPubMedCentral Le BV, Griffin CR, Loeb S, et al. [−2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol. 2010;183:1355–9.CrossRefPubMedPubMedCentral
3.
go back to reference Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [−2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomark Prev. 2010;19:1193–200.CrossRef Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [−2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomark Prev. 2010;19:1193–200.CrossRef
4.
go back to reference Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [−2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185:1650–5.CrossRefPubMedPubMedCentral Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [−2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185:1650–5.CrossRefPubMedPubMedCentral
5.
go back to reference Lazzeri M, Haese A, Taille Adl, et al. Serum isoform [−2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: a multicentric European study. Eur Urol. 2013;63:986–94.CrossRefPubMed Lazzeri M, Haese A, Taille Adl, et al. Serum isoform [−2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: a multicentric European study. Eur Urol. 2013;63:986–94.CrossRefPubMed
6.
go back to reference Lughezzani G, Lazzeri M, Haese A, et al. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol. 2014;66:906–12.CrossRefPubMed Lughezzani G, Lazzeri M, Haese A, et al. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol. 2014;66:906–12.CrossRefPubMed
7.
go back to reference Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A. Multicenter evaluation of [−2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem. 2013;59:306–14.CrossRefPubMed Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K, Semjonow A. Multicenter evaluation of [−2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem. 2013;59:306–14.CrossRefPubMed
8.
go back to reference Ng CF, Chiu PKF, Lam N, Lam H, Lee K, Hou SSM. The prostate health index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL. Int Urol Nephrol. 2014;46:711–7.CrossRefPubMed Ng CF, Chiu PKF, Lam N, Lam H, Lee K, Hou SSM. The prostate health index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL. Int Urol Nephrol. 2014;46:711–7.CrossRefPubMed
9.
go back to reference Guazzoni G, Lazzeri M, Nava L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol. 2012;61:455–66.CrossRefPubMed Guazzoni G, Lazzeri M, Nava L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol. 2012;61:455–66.CrossRefPubMed
10.
go back to reference Eminaga O, Bögemann M, Breil B, et al. Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy. Urol Oncol. 2014;32:1117–26.CrossRef Eminaga O, Bögemann M, Breil B, et al. Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy. Urol Oncol. 2014;32:1117–26.CrossRef
11.
go back to reference Fossati N, Buffi NM, Haese A, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric European prospective study. Eur Urol. 2015;68:132–8.CrossRefPubMed Fossati N, Buffi NM, Haese A, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric European prospective study. Eur Urol. 2015;68:132–8.CrossRefPubMed
12.
13.
go back to reference Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol. 1994;152:1721–9.PubMed Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol. 1994;152:1721–9.PubMed
14.
go back to reference Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368–74.CrossRefPubMed Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368–74.CrossRefPubMed
15.
go back to reference Semjonow A, Köpke T, Eltze E, Pepping-Schefers B, Burgel H, Darte C. Pre-analytical in vitro stability of [−2]proPSA in blood and serum. Clin Chem. 2010;43:926–8. Semjonow A, Köpke T, Eltze E, Pepping-Schefers B, Burgel H, Darte C. Pre-analytical in vitro stability of [−2]proPSA in blood and serum. Clin Chem. 2010;43:926–8.
16.
go back to reference Epstein JI, Allsbrook WC, Amin MB, Egevad LL (2005) The International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–42.CrossRefPubMed Epstein JI, Allsbrook WC, Amin MB, Egevad LL (2005) The International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–42.CrossRefPubMed
18.
go back to reference Anast JW, Andriole GL, Bismar TA, Yan Y, Humprey PA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology. 2004;64:544–50.CrossRefPubMed Anast JW, Andriole GL, Bismar TA, Yan Y, Humprey PA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology. 2004;64:544–50.CrossRefPubMed
19.
go back to reference Autorino R, Lorenzo GD, Damiano R, et al. Pathology of the prostate in radical cystectomy specimens: a critical review. Surg Oncol. 2009;18:73–84.CrossRefPubMed Autorino R, Lorenzo GD, Damiano R, et al. Pathology of the prostate in radical cystectomy specimens: a critical review. Surg Oncol. 2009;18:73–84.CrossRefPubMed
20.
go back to reference Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int. 2011;108:1074–85.CrossRefPubMed Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int. 2011;108:1074–85.CrossRefPubMed
Metadata
Title
Prostate Health Index and %p2PSA Predict Aggressive Prostate Cancer Pathology in Chinese Patients Undergoing Radical Prostatectomy
Authors
Peter Ka-Fung Chiu, MBChB, FRCSEd (Urol), FHKAM (Surg)
Fernand Mac-Moune Lai, MD (Lyon), FRCPA, FHKCPath, MScFl (Leicester)
Jeremy Yuen-Chun Teoh, MBBS, MRCSEd
Wai-Man Lee, Msc
Chi-Hang Yee, MBBS, FRCSEd (Urol), FHKAM (Surg)
Eddie Shu-Yin Chan, MD, MBChB, FRCSEd (Urol), FHKAM (Surg)
See-Ming Hou, MBBS, FRCSEd (Urol), FHKAM (Surg)
Chi-Fai Ng, MD, MBChB, FRCSEd (Urol), FHKAM (Surg)
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2016
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5183-6

Other articles of this Issue 8/2016

Annals of Surgical Oncology 8/2016 Go to the issue